DK175699B1 - Nucleinsyremolekyle, rekombinant DNA-vektor indeholdende nucleinsyremolekylet, rekombinant ekspressionsvektor indeholdende nucleinsyremolekylet, celle indeholdende nucleotidsekvensen, oplöseligt CR1-polypeptid, fremgangsmåde til fremstilling ............. - Google Patents

Nucleinsyremolekyle, rekombinant DNA-vektor indeholdende nucleinsyremolekylet, rekombinant ekspressionsvektor indeholdende nucleinsyremolekylet, celle indeholdende nucleotidsekvensen, oplöseligt CR1-polypeptid, fremgangsmåde til fremstilling ............. Download PDF

Info

Publication number
DK175699B1
DK175699B1 DK199002348A DK234890A DK175699B1 DK 175699 B1 DK175699 B1 DK 175699B1 DK 199002348 A DK199002348 A DK 199002348A DK 234890 A DK234890 A DK 234890A DK 175699 B1 DK175699 B1 DK 175699B1
Authority
DK
Denmark
Prior art keywords
polypeptide
soluble
scr1
cell
nucleic acid
Prior art date
Application number
DK199002348A
Other languages
Danish (da)
English (en)
Other versions
DK234890A (da
DK234890D0 (da
Inventor
Douglas T Fearon
Lloyd B Klickstein
Winnie W Wong
Gerald R Carson
Michael F Concino
Stephen H Ip
Savvas C Makrides
C Marsh Henry Jr
Original Assignee
Brigham & Womens Hospital
Univ Johns Hopkins
Avant Immunotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital, Univ Johns Hopkins, Avant Immunotherapeutics Inc filed Critical Brigham & Womens Hospital
Publication of DK234890D0 publication Critical patent/DK234890D0/da
Publication of DK234890A publication Critical patent/DK234890A/da
Application granted granted Critical
Publication of DK175699B1 publication Critical patent/DK175699B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153—Streptokinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Joining Of Building Structures In Genera (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK199002348A 1988-04-01 1990-09-28 Nucleinsyremolekyle, rekombinant DNA-vektor indeholdende nucleinsyremolekylet, rekombinant ekspressionsvektor indeholdende nucleinsyremolekylet, celle indeholdende nucleotidsekvensen, oplöseligt CR1-polypeptid, fremgangsmåde til fremstilling ............. DK175699B1 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US17653288A 1988-04-01 1988-04-01
US17653288 1988-04-01
US8901358 1989-03-31
PCT/US1989/001358 WO1989009220A1 (en) 1988-04-01 1989-03-31 THE HUMAN C3b/C4b RECEPTOR (CR1)
US41274589A 1989-09-26 1989-09-26
US41274589 1989-09-26

Publications (3)

Publication Number Publication Date
DK234890D0 DK234890D0 (da) 1990-09-28
DK234890A DK234890A (da) 1990-11-30
DK175699B1 true DK175699B1 (da) 2005-01-24

Family

ID=26872337

Family Applications (1)

Application Number Title Priority Date Filing Date
DK199002348A DK175699B1 (da) 1988-04-01 1990-09-28 Nucleinsyremolekyle, rekombinant DNA-vektor indeholdende nucleinsyremolekylet, rekombinant ekspressionsvektor indeholdende nucleinsyremolekylet, celle indeholdende nucleotidsekvensen, oplöseligt CR1-polypeptid, fremgangsmåde til fremstilling .............

Country Status (14)

Country Link
EP (1) EP0411031B1 (es)
JP (1) JP3484189B2 (es)
CN (2) CN1092712C (es)
AT (1) ATE240973T1 (es)
CA (2) CA1340866C (es)
DE (1) DE68929466T2 (es)
DK (1) DK175699B1 (es)
ES (1) ES2014593A6 (es)
FI (2) FI106316B (es)
IL (1) IL89790A (es)
NO (1) NO315944B1 (es)
SG (1) SG52789A1 (es)
WO (1) WO1989009220A1 (es)
ZA (2) ZA892397B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5426029A (en) * 1986-03-31 1995-06-20 T Cell Diagnostics, Inc. Therapeutic and diagnostic methods using leukocyte surface antigens
US5256642A (en) * 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
US6482404B1 (en) 1989-10-12 2002-11-19 David James White Transplantation of tissue comprising a DNA sequence encoding a homologous complement restriction factor
ES2060561T3 (es) * 1989-10-12 1996-08-01 Imutran Ltd Material biologico modificado.
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6458360B1 (en) * 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
WO1992009698A1 (en) * 1990-11-26 1992-06-11 Genetics Institute, Inc. Expression of pace in host cells and methods of use thereof
JPH06503344A (ja) * 1990-12-06 1994-04-14 ティーセル　サイエンシズ，インコーポレーテッド 可溶性の補体受容体と、補体を抑制しかつ／または免疫活性を抑制する化合物との相乗組成物
EP0512733A2 (en) * 1991-05-03 1992-11-11 Washington University Modified complement system regulator
DE69328098T2 (de) * 1992-06-24 2000-08-24 Adprotech Plc, Royston Lösliche derivate des complement type-rezeptors (cr1)
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
DE69431290D1 (de) * 1993-02-12 2002-10-10 Avant Immunotherapeutics Inc PULMONÄRE VERABREICHUNG DES LÖSLICHEN KOMPLEMENT-RECEPTORS TYP 1 sCR1
BR9708387A (pt) 1996-03-28 2000-01-04 Genitrix Llc Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
GB9706950D0 (en) * 1997-04-05 1997-05-21 Chernajovsky Yuti Immune modulation by polypeptides related to CR1
US6664052B1 (en) 1998-07-24 2003-12-16 The Uab Research Foundation Genetic polymorphism in a complement receptor
WO2000005413A1 (en) * 1998-07-24 2000-02-03 Uab Research Foundation Genetic polymorphism in a complement receptor
GB9905503D0 (en) 1999-03-10 1999-05-05 Adprotech Plc Novel compound formulations and methods of delivery
EP1738763A1 (en) 2005-06-30 2007-01-03 AVANT Immunotherapeutics, Inc. Use of complement inhibitory proteins to treat spinal cord injury
AU2007307375B2 (en) 2006-10-10 2013-11-28 Regenesance B.V. Complement inhibition for improved nerve regeneration
CN102245765B (zh) 2008-10-21 2015-01-07 通用医院公司 细胞移植
EP3530741B1 (en) 2010-08-06 2021-04-07 The General Hospital Corporation D/B/A Massachusetts General Hospital System and apparatus for cell treatment
US9295713B2 (en) 2010-09-15 2016-03-29 Celldex Therapeutics, Inc. Treatment of chronic nephropathies using soluble complement receptor type I (sCR1)
WO2012058479A2 (en) 2010-10-27 2012-05-03 Celldex Therapeutics, Inc. Method of improving transplant function using soluble complement receptor type i (scr1)
ES2564290T3 (es) * 2010-11-02 2016-03-21 Kypha, Inc. Inmunoensayo de flujo lateral para la activación de complemento y métodos de uso para evaluación del sitio de atención de trastornos asociados a complemento
CN102702339B (zh) * 2011-05-24 2013-10-30 华南师范大学 斜带石斑鱼补体c3基因、载体、重组菌株和蛋白及其应用
BR112014013205A2 (pt) * 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
CN104293836A (zh) * 2014-06-24 2015-01-21 长沙赢润生物技术有限公司 一种免疫复合物吸附细胞的制作方法
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
EP3760645A1 (en) * 2019-07-02 2021-01-06 imusyn GmbH & Co. KG Analysis for blood group antigen dacy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60192948A (ja) * 1984-03-14 1985-10-01 Fuji Photo Film Co Ltd 湿し水不要ネガ型感光性平版印刷版および製版方法
US4672044A (en) * 1984-08-24 1987-06-09 Scripps Clinic & Research Foundation Murine monoclonal antibody combining site to human C3b receptor (CR1)

Also Published As

Publication number Publication date
ES2014593A6 (es) 1990-07-16
ZA907693B (en) 1992-05-27
ATE240973T1 (de) 2003-06-15
CA1340866C (en) 1999-12-28
EP0411031A1 (en) 1991-02-06
DK234890A (da) 1990-11-30
DK234890D0 (da) 1990-09-28
WO1989009220A1 (en) 1989-10-05
JP3484189B2 (ja) 2004-01-06
IL89790A (en) 2002-05-23
CN1053265A (zh) 1991-07-24
ZA892397B (en) 1989-11-29
CN1092712C (zh) 2002-10-16
JPH04501502A (ja) 1992-03-19
SG52789A1 (en) 1998-09-28
NO315944B1 (no) 2003-11-17
CA1341443C (en) 2003-10-07
EP0411031A4 (en) 1992-02-05
NO20000827D0 (no) 2000-02-18
NO20000827L (no) 1990-11-09
AU647371B2 (en) 1994-03-24
FI115528B (fi) 2005-05-31
FI20002515A (fi) 2000-11-16
AU3539489A (en) 1989-10-16
DE68929466D1 (de) 2003-06-26
IL89790A0 (en) 1989-09-28
FI904842A0 (fi) 1990-10-01
CN1036987A (zh) 1989-11-08
EP0411031B1 (en) 2003-05-21
CN1053924C (zh) 2000-06-28
DE68929466T2 (de) 2004-04-01
FI106316B (fi) 2001-01-15

Similar Documents

Publication Publication Date Title
DK175699B1 (da) Nucleinsyremolekyle, rekombinant DNA-vektor indeholdende nucleinsyremolekylet, rekombinant ekspressionsvektor indeholdende nucleinsyremolekylet, celle indeholdende nucleotidsekvensen, oplöseligt CR1-polypeptid, fremgangsmåde til fremstilling .............
US6316604B1 (en) Human C3b/C4b receptor (CR1)
AU656312B2 (en) The human C3b/C4b receptor (CR1)
US5981481A (en) Human C3b/C4b receptor (CR1)
US6294352B1 (en) TNF receptors, TNF binding proteins and DNAs coding for them
US5208144A (en) Method for detection of human dna containing the gene encoding low density lipoprotein receptor
US6083688A (en) Platelet glycoprotein V gene and uses
US6221675B1 (en) TNF receptors, TNF binding proteins and DNAs coding for them
EP0682113A2 (en) Polypeptide produced in an endothelial cell line and DNA encoding it
KR0143570B1 (ko) 사람 C3b/C4b 수용체(CR1)단백질, 이의 정제 방법 및 이의 용도
AU647371C (en) The human C3b/C4b receptor (CR1)
CA2166872A1 (en) Platelet glycoprotein v gene and uses
EP0358977A1 (en) Cloned nephritis antigen
NO310078B1 (no) Nukleinsyresekvens kodende for CR1-protein, ekspresjonsvektor samt rekombinant celle omfattende nevnte sekvens og en fremgangsmåte for å fremstille nevnte protein
WO1995004756A1 (en) Complement inhibitor proteins of non-human primates
JPH0823977A (ja) 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたは抗体を含有する薬学的組成物
WO1997012898A1 (en) Novel platelet activation protein

Legal Events

Date Code Title Description
PBP Patent lapsed

Country of ref document: DK